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Summary Patients with ovarian cancer often respond well to combination chemotherapy initially but the
majority eventually relapse when, with further treatment, the initially successful regimen proves ineffectual.
The cause of such failures frequently has been attributed to the development of drug resistance. Although
the mechanisms of acquired resistance in situ are still poorly understood, studies in vitro have shown that cells
selected for resistance to one drug often exhibit cross-resistance to other seemingly unrelated agents,
suggesting a somewhat generalised mechanism of resistance. We have studied the role of glutathione (GSH)
and drug transport in determining the sensitivity to adriamycin (ADR) of a panel of human ovarian cell lines
established directly from biopsies of patients with diverse treatment histories. These cell lines exhibited
inherent differences in sensitivity to ADR by a dose factor of up to 3; a difference that was considerably less
than what has been reported when cells were selected for drug resistance in vitro. The differences in drug
sensitivity reported here among the various cell lines appeared to be unrelated to drug transport, in terms of
both influx and efflux. Moreover, although these cell lines have a wide range of GSH content, there was only
a poor correlation between drug sensitivity and cellular GSH content per se. However, when exposed to a
clinically relevant dose of ADR, the GSH content of cell lines that were 'sensitive' decreased, whereas that of
cell lines that were 'resistant' increased. To take these time-dependent changes in GSH into consideration, the
area under the GSH content versus time curve (AUC), with and without ADR treatment, was calculated for
each cell line. When this latter factor was included in the analysis, greatly improved correlations were found
between GSH kinetic parameters and responses to ADR. In particular, ADR resistance was found to be
closely correlated with the positive changes in absolute GSH AUC following ADR treatment (r=0.92;
P<0.01). Using 35S-labelled cysteine and methionine as tracers, it was found that the essential difference
between the 'resistant' and 'sensitive' lines was that the 'resistant' lines had higher steady-state rates of GSH
synthesis than the 'sensitive' lines. These results demonstrate that changes in cellular GSH concentration
during treatment may be an important indicator of tumour cell response to ADR.
The role of glutathione (GSH) in the development of drug
and radiation resistance in cancer cells is a subject of much
current research effort. Although the mechanism(s) by which
GSH protects cells from the damaging effects of cytotoxic
agents is still not fully understood, it is now clear that GSH
can greatly influence the intrinsic sensitivity of tumour cells
to radiation (Biaglow et al., 1983; Shrieve et al., 1985;
Revesz, 1985) and to a variety of cytotoxic drugs (Hamilton
et al., 1985; Suzukake et al., 1982; Green et al., 1984; Crook
et al., 1986; Lee et al., 1988; Kramer et al., 1987. However,
previous studies have focused only on the importance of the
initial, pretreatment GSH contents in drug sensitive vis a' vis
resistant cell lines. An indication that this may not be the
only determining factor involving GSH was obtained in a
series of experiments in which the role of GSH in modul-
ating cellular response to adriamycin (ADR) was assessed
using the human tumour HEp3 cell line (Lee et al., 1988). It
was observed that upon challenge with ADR, cellular GSH
levels underwent a rapid decrease followed by a more
gradual increase to a level significantly above the pre-
treatment concentration. These interesting kinetic changes in
GSH concentration have prompted us to investigate in detail
both the role of initial GSH steady-state concentration per se
and the kinetic changes induced by cytotoxic challenge either
as possible determining factors and/or indicators of cellular
response to ADR. These studies were performed with a
panel of human ovarian tumour cell lines established in this
laboratory directly from both treated and untreated patients.
ADR was chosen for this investigation because of its exten-
sive use in combination therapy of ovarian cancer. Further-
more, the propensity of ADR to generate reactive ADR as
well as oxygen radicals and hydrogen peroxide made it well-
suited for probing the enzyme-dependent and -independent
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free-radical scavenging properties of GSH and its role in
acquired drug resistance.
Materials and methods
Drugs
Adriamycin (ADR) was obtained from Adria Laboratories
Inc. (Columbus, OH). The metabolites of ADR (7-deoxy-
adriamycinone, adriamycinol, 7-deoxy-13-dihydroadria-
mycinone and adriamycinone) were kindly provided by Dr
Mervyn Israel, Department of Pharmacology, University of
Tennessee. Synthetic GSH standard was obtained from
Sigma Chemical Company (St Louis, MO).
Cell lines and culture conditions
The human ovarian adenocarcinoma cell lines, except OW-1,
were established directly in this laboratory from patients'
biopsies. Tumour cells were purified from solid tumours,
ascites or cyst fluids by centrifugal elutriation. Cultures were
initiated on bovine corneal matrix-coated dishes in alpha-
MEM containing 10% fetal calf serum (FCS) (J.R. Scien-
tific, Woodland, CA) and 20% conditioned medium. The
OW-1 line was generously supplied by Dr R. Buick (Ontario
Cancer Institute, Toronto) for comparison. The pathology
and treatment status of each patient is given in Table I. All
cultures, except SAU, were maintained in alpha-MEM
medium supplemented with 10% FCS, 5mM glutamine and
10mM HEPES. The growth conditions for SAU were essen-
tially the same as others but without HEPES.
Adriamycin treatment
ADR was dissolved in phosphate buffer saline solution
(PBS), pH 7.4, at a concentration of 1 mgml1I and stored at
-75°C for no longer than 4 weeks.
Exponentially growing cells cultured in 75cm2 plastic
flasks (Corning) were washed once with Ca2+ and Mg+2_
free PBS, and trypsinised with 0.01% trypsin (Worthington)/
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Table I Origin and treatment history of the human ovarian cell lines
Cell linea Treatmentb Cell line derived
ATW CAP/BCG Post-chemotherapy
PEA Cytoxan, 1 course At diagnosis (pre-chemotherapy)
SAU CAP/BCG, 3 courses At diagnosis (pre-chemotherapy)
GRA CAP, 6 courses Post-chemotherapy
(partial response)
OW-lc Melphalan, 1 year Post-chemotherapy
CAP, 5 months
MLS CAP, 9 courses After relapse from CAP only
Initial good response.
Recurred 2 months post-CAP
Tamoxifen, 3 months
5-FU-MTX, 2 courses
Depoprovera, 1 month
SKA Cytoxan, 5 courses Post chemotherapy
Adriamycin, 4 courses
Tamoxifen, 2 months
5-FU-MTX, 6 courses
aCell lines, except for OW-1, were derived directly from patients' biopsies (see Materials
and methods). bAbbreviations are: CAP, cyclophosphamide (cytoxan), adriamycin, cisplatin;
BCG, bacillus Calmette-Guerin; 5-FU, 5-fluorouracil; MTX, methotrexate. cGratefully
received from Dr R. Buick.
0.02% EDTA (Sigma). Single cells were suspended at a
concentration of 2.5 x 105 cellsml-I in complete media plus
10% FCS in a type I vial at 37°C as described by Whillans
& Rauth (1980). During the entire incubation period, cells
were continuously gassed with 95% air/5% CO2 gas mixture.
After equilibration for 30min, a l0yl aliquot of a stock
solution of ADR was given per ml of cells. At the end of
drug exposure, a I ml aliquot of cells was removed and
washed by centrifugation through 14ml of cold medium at
400g for 10min at 4°C. The cell pellet was resuspended in
complete medium plus FCS, the cell number counted and
survival determined by clonogenic assay. At various times
after plating (12-21 days), depending on the cell lines, the
dishes were stained with crystal violet. Colonies containing
greater than 50 cells were counted to determine cell survival.
High-performance liquid chromatography (HPLC)
Cellular GSH content and ADR transport were both assayed
by paired-ion HPLC. The HPLC equipment (Waters
Associates, Milford, MA, USA) consisted of Model 600A
chromatography pumps, Model 710B Automated Sample
Processors (WISP), Data Module, Model 720 system
controller, Z-module and Model 420 fluorescence detector.
Sample preparation for GSH determination
At different times during drug exposure aliquots of cells
were removed for HPLC analysis. Cells were homogenised
with a 200 p1 aliquot of 20mM 5-sulphosalicylic acid (Sigma).
The homogenates were centrifuged for 40s in an Eppendorf
microcentrifuge. GSH in the supernatant was derivatised
with the fluorescent agent monobromobimane (Thiolyte,
Calbiochem). The reaction mixture contained 180pl of the
supernatant, 12pl N-ethylmorpholine (O.5 M in 2.0mM KOH)
and 2pl of monobromobimine (50mM in acetonitrile). The
mixture was immediately vortexed and stored in the dark at
4°C before analysis.
GSH was separated from other fluorescent materials on
Waters Radial-PAk reversed-phase bonded octadecylsilane
(C18) cartridge columns (8mm i.d.), 5pm diameter spherical
particles. Isocratic elution was carried out with a mobile
phase of 23% acetonitrile in 40mM ammonium phosphate
buffer, pH7.2, containing 5 mM tetra-butylammonium
hydroxide. The flow rate was 3mlmin-1. Fluorescence was
monitored with 340 nm excitation and emission at >410 nm.
GSH was identified by co-chromatography with authentic
GSH standards. Quantitation was carried out on the basis of
peak height with reference to calibration curve, which was
linear over the range 0.65-65nM. With the above method,
the coefficient of variation was 7.2% at a concentration of
6 nM. The lower limit of detection was approximately 0.4 nM.
For the study of GSH synthesis, a gradient elution
procedure of 10min duration, commencing at time zero,
from 10% to the final condition of 23% acetonitrile in 40nM
ammonium phosphate buffer, pH7.2, containing 5 mM tetra-
butylammonium hydroxide at a flow rate of 2mlmin1 was
used throughout.
Determination of GSH synthesis rate using 35S-cysteine and
35S-methionine
Exponentially growing cells were incubated with 1 pCiml-1
35S-labelled cysteine or with 5pCimI-1 35S-labelled
methionine dissolved in alpha-MEM medium for 3h at
37°C. Cells were then washed, trypsinised and prepared for
GSH analysis by HPLC as described above. Fractions of the
HPLC effluent were collected every 30s. The amount of
radioactivity in each fraction was measured by a liquid
scintillation counter (Searle).
Table II Sensitivity to ADR, cell volume, amount of protein per 106 cell and GSH content represented as amount of GSH per cell, per
volume and per ug protein of the various human ovarian cell lines. All values were means from four experiments +s.d.
GSH content
Cell Cell volume Mlg protein per 106 ICgo for ADR'
line (Cm3) cells fg protein m-3 fmolcelll x 10-8 molpst-3 nmol per mg protein (pgml-)
ATW 5,630+1,110 522+15 92.7+10.4 24.8+ 3.1 4.5+0.6 47.5+4.2 0.47.
PEA 2,700+ 760 273+26 101 + 9.1 14.9+ 2.5 5.5+0.5 54.6+4.8 0.41
SAU 6,160±1,630 950+46 154 +12.5 52.0+11.0 7.7+0.6 54.7+3.7 0.50
GRA 3,240+ 580 470+ 5 145 +10.3 24.3+ 1.5 7.5±0.3 51.7+4.0 0.35
OW-1 2,460+ 50 221+10 89.8+ 7.8 14.8+ 2.0 6.0+0.5 67.0+5.6 0.62
SKA 4,020+ 180 695+50 173 +14.9 22.9+ 3.0 5.7+0.3 32.9+3.4 0.67
MLS 2,820+ 600 240+19 85.1+ 9.2 22.0+ 1.5 7.8+3.5 91.7+7.7 0.84
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Figure 1 The effects of ADR on the intracellular GSH content of various human ovarian cell lines. *, ATW; A, PEA; V, SAU;
V, GRA; *, OW-1; 0, SKA; 0, MLS. Cells were exposed in suspension to jgml- ADR during the entire measuring period
(3h). At various times, aliquots of cells were sampled for GSH measurement by HPLC as described in Materials and methods.
Each datum point was the mean of three individual determinations. Two repeated experiments gave similar results.
Sample preparation for adriamycin transport studies.
Cells treated with ADR (1 pgml-1) in suspension for h
were separated from drug-containing medium by centri-
fugation through a layer of corn oil/dibutylphthlate mixture
(1:4v/v). Following membrane disruption by sonification,
cell sonicates or ADR containing media were extracted with
5 volumes of ethyl-acetate: 1-propanol (9: 1 v/v). The extracts
were evaporated to dryness either under a stream of dry
nitrogen gas or in vacuo using a Savant Speed Vac Concen-
trator (Savant Instruments Inc., Hicksville, NY). The dry
residues were redissolved in 100 p1 methanol (HPLC grade)
and stored sealed at -20°C. Aliquots (35-70 p1) of the
methanol concentrate were used for HPLC analyses.
Adriamycin and its metabolites were separated on Waters
Nova-PAK phenyl cartridge column (8mm i.d., 4pm particle
size). Samples were eluted by running a linear gradient of
acetonitrile/formic acid buffer, pH4.0, from 25% to the final
condition at 6min of 50% acetonitrile in formic acid. The
flow rate was 3.0mlmin-1. Detection was by fluorescence
with excitatioin at 500nM and emission at >650nM.
Protein assay
Cells (5 x 105) were resuspended in 400Ml distilled H2 and
cell membrane disrupted by a sonifier cell disruptor (Branson
Sonic Power Co., Plainview, NY) and protein was assayed
with the Bio-Rad protein assay (Richmond, CA) using
bovine serum albumin, fraction V as the standard.
Cell volume estimation
Single cells were suspended in PBS at a concentration of 2-
4 x 104 cellsml-1, and cell volume was determined by a
model ZBI Coulter Counter equipped with a model CI000
channelyser from Coulter Corp. (Hialeah, FL).
Area under the GSH concentration-time curve (AUC)
Area under the GSH concentration-time curve was calcu-
lated for the duration of ADR exposure from time 0 to 3h
(AUCG03Jh) by numerical integration using Simpson's Rule
(see Gilbaldi & Perrier, 1982). Coefficients of correlation
were calculated by linear regression analyses and tests of
significance were by Student's t distribution.
Results
GSH contents of ovarian tumour cell lines
Table II gives the cell volume, protein and GSH contents of
seven ovarian tumour cell lines established directly from
patients' tumour biopsies. The cell volume of these cell lines
ranged from 2,460 to 6,160 pm3, whereas their protein
content varied from 221 to 950pg protein per 106 cells. Even
when corrected for cell volume variation, the protein content
still differed greatly among the cell lines, ranging from 85.1
to 154fg protein per pm3, indicating a significant hetero-
geneity among the cell lines in terms of protein content. We
have therefore chosen, for the purpose of comparison
between cell lines, to express GSH content in terms of GSH
per volume (fmolpm-3). This unit is also physically a truer
representation of cellular concentration since GSH is distri-
buted throughout the cytosol as well as in the nucleus. In the
ovarian tumour lines, GSH content ranged from 14.8 to
52.0fmolcell-1 on a per cell basis, or from 32.9 to 91.7pmol
per pg protein on a per protein basis. These rather large
Table III Relative rates of GSH synthesis in the ovarian tumour cell lines
incubated in medium containing 35S-cysteine
Relative rates of GSH synthesis (c.p.m.)
Cell line Experiment I Experiment 2 Experiment 3 Experiment 4
PEA 3,120+110 3,340+160 7,820+240 3,010+145
SAU 1,980+ 105 3,530+ 90 7,790+300 3,990+180
GRA 2,240+ 95 3,490+140 8,100+420 3,320+ 175
OW-1 1,590+ 70 3,920+145 9,240+435 3,710+130
SKA 5,370+210 4,960+260 11,780+525 5,370+230
MLS 5,450+285 7,070+335 13,830+670 5,670+400
Values are means +s.d. of triplicates.294 F.Y.F. LEE et al.
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Figure 2 The relationship between clonogenic cell survival of the various ovarian cell lines and (a) area under the GSH content-
time curve (AUCO3h), and (b) changes in the area under the GSH content-time curve (AAUCO3h)j *, ATW; A, PEA; V, SAU;
7, GRA; *, OW-1; 0, SKA; 0, MLS. Cells were exposed in suspension to pgml-l ADR. For GSH determination and
clonogenic cell survival see Figure I and Table II respectively. Error bars represent +s.d.
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Figure 3 HPLC chromatograms of 35S-labelled GSH in the
cellular extract obtained from the human ovarian cell line MLS
following incubation with 1 iCiml-i 35S-cysteine for 4h.
variations in GSH content among the cell lines were greatly
reduced when GSH was expressed on a per volume basis,
being 4.5-7.8 x 10-3 fmol,m-3 (Table II).
Effects ofADR treatment on the GSH content of tumour cells
The effects of ADR on tumour cell GSH content were
studied in all the ovarian tumour cell lines. Control groups
not exposed to ADR maintained their GSH contents at a
steady level throughout the duration of the experiment. The
GSH contents of treated groups were always compared to
those of their corresponding parallel control groups. Figure
1 shows the changes of GSH concentration with time for the
various ovarian tumour cell lines when treated with ADR
(1 ig ml-1). Upon exposure, there was a small initial
decrease (statistically not significant, P>0.1) in GSH con-
centration at 15-30min. Some cell lines recovered readily
from the early drop in GSH concentration to reach levels
above the initial pretreatment values. On the other hand, a
few cell lines exhibited depleted GSH content throughout the
entire 3h measuring period. These differences in GSH con-
centration kinetics following ADR treatment were cell line
specific but were not related to the cell's initial GSH
concentration (Table II). To take into account both the
initial GSH concentration and the changes in GSH contents
during the 3h ADR treatment, GSH kinetics parameters (i.e.
area under the GSH concentration-time curve) were calcu-
lated for each cell line from data shown in Figure 1 in terms
of (1) absolute AUCO3h, (2) changes in absolute AUCO3h
(AAUCO3h) compared to untreated controls, and (3)
percentage changes in absolute AUCO.3h (% AAUCO-3h)
compared to untreated controls (see below).
Sensitivity to ADR cytotoxicity - relationship to changes in
GSH kinetics
The ovarian tumour cell lines showed a spectrum of sensiti-
vities to ADR. The difference in sensitivity between the most
and the least sensitive lines, GRA and MLS respectively,
were 2 and 3.6-fold at surviving fractions of 0.1 (IC90) and
0.01 respectively. The relationship between cell survival and
GSH was also investigated in a series of experiments in
which, for the same cell population, cell survival was moni-
tored with respect to GSH content per cell, GSH content per
volume, GSH content per mg protein and the GSH AUC
kinetics parameters (for explanation see above). The intrinsic
sensitivity of the ovarian tumour cell lines did not appear to
correlate with their GSH contents, whether expressed on a
per cell (r=0.159; P>0.1), per volume (r=0.069; P>0.1) or
per mg protein basis (r=0.043; P>0.1) (Table II). With
GSH AUC kinetics parameters, however, a high degree
of positive correlation could be predicted between these
parameters and cellular sensitivity to ADR (Figure 2). A
highly significant degree of correlation was observed with
AAUCO3h (r=0.92; P<0.01) (Figure 2a). Slightly lower but
still statistically significant degrees of correlation were also
observed with % AAUCO3h (r=0.86; P<0.02) and with
absolute AUCO3h (r=0.77; P<0.05) (Figure 2b).
Effects of ADR treatment on the rate of GSH synthesis
35S-cysteine and 35S-methionine were used as tracers to
monitor the rate of GSH synthesis. Figure 3 shows that the
HPLC fluorescence peak corresponded exactly to the radio-
activity peak. The amount of labelled GSH synthesised was
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Figure 4 Percentage changes from control in the rate of GSH
synthesis in human ovarian tumour cell lines incubated with
lgmlPl ADR. Cells were co-incubated with ADR and 35S-
cysteine for 4h. Different symbols represent independent
experiments.
directly dependent on the amount of labelled 35S-cysteine in
the medium (data not shown). With a fixed quantity of
labelled 35S-cysteine (1 pCiml- 1) the total GSH related
radioactivity was directly proportional to the incubation time
up to 12h (data not shown). In all the following experiments
where the rates of GSH synthesis were compared, cells were
incubated with 1 pCiml- of 3 S-cysteine of 5 pCiml1 35S-
methionine as substrates for 4h. The basal rates of GSH
synthesis varied by up to 1.85 and 2.1-fold among the cell
lines using 35S-cysteine and 35S-methionine as substrates
respectively (Tables III and IV). Comparing Tables II, III
and IV, it can be seen that the more 'resistant' cell lines
generally had higher rates of GSH synthesis than did the
'sensitive' cell lines. Note that these results held true
irrespective of whether 35S-cysteine or 35S-methionine was
used as the tracer. Under the oxidative stress imposed by
ADR (1 ugml-1) the rates of GSH synthesis were increased
significantly (P<0.05) in all cell lines by similar degrees
above basal rates, i.e. 4-6% (Figure 4). In real terms, the
increases in the cell lines with higher steady-state synthesis
rates were of course greater than in the cell lines with lower
synthesis rates.
ADR accumulation and efflux
ADR accumulation and efflux were measured by HPLC in
all the ovarian tumour cell lines following 1 h incubation
with 1 pgml- 1 (1.85 pM) ADR. The parent ADR was readily
detected and quantitated but none of its metabolites were
found in any of the cell lines. Figure 5a is a typical HPLC
chromatogram of the authentic synthetic standards of ADR
and its metabolites. Figure 5b is a HPLC chromatogram of
the cellular extract of MLS where only the parent ADR was
detected. Table V lists the cellular ADR accumulation data,
i.e. ADR concentration following the 1 h incubation period
but immediately before washing with PBS. Also shown in
Table V are the cellular ADR concentrations 2h after
washing with PBS. These latter values were taken as a
Table IV Relative rates of GSH synthesis in the ovarian
tumour cell lines incubated in medium containing
35S-methionine
Relative rates of GSH
synthesis (c.p.m.)
Cell line Experiment I Experiment 2
PEA 660+ 45 710+ 60
SAU 730+ 85 540+ 60
GRA 470+ 65 420+ 45
OW-1 840+ 90 920+ 80
SKA 1,120±140 1,360±180
MLS 1,290±130 1,520±200
Values are means +s.d. of triplicate determinations.
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Figure 5 a, HPLC chromatogram of authentic ADR and its
four major metabolites. Peak 1, adriamycinol; peak 2, adria-
mycin; peak 3, 7-deoxy-13-di-hydro-adriamycinone; peak 4,
adriamycinone; peak 5, 7-deoxy-adriamycinone (gifts from Dr
Mervyn Israel, University ofTennessee). b, HPLC chromatogram
of the cellular extract obtained from the human ovarian cell line
MLS following treatment with ADR (1 tgml-1) for h.
measure of the rate of efflux of cellular ADR. The ADR
concentration in the culture media, as measured by HPLC at
the end of the 1 h incubation, was 0.161+0.018
(+s.d.) x 10 19mol pm- . The intracellular concentrations of
free ADR in the ovarian tumour cell lines therefore exceeded
that of the extracellular ADR concentration by 16 to 26-
fold, but the differences in accumulation between the cell
lines were not statistically significant (P>0.05). The rates of
ADR efflux also were not significantly different among the
cell lines. Intracellular ADR concentrations were 3-6% of
the accumulated ADR concentration 2h after washing the
cells free of extracellular ADR (Table V). Neither cellular
ADR accumulation nor effiux rates appeared to correlate
with the intrinsic sensitivity of the cell lines to ADR.
Discussion
The present results show that the sensitivity of a panel of
human ovarian tumour cell lines to ADR does not depend
on the initial, steady-state GSH content per se. However, the
ability of the cells to maintain an appropriate GSH level in
the face of the oxidative stress imposed by ADR appears to
be important for cell survival, although whether this capacity
is directly responsible for ADR resistance is still unclear.
The maintenance of a high GSH content may be beneficial
to a cell in two ways: (1) by increasing the ability to
scavenge cytotoxic free radicals; (2) by maintaining a viable
Table V Intracellular ADR concentrations in various human
ovarian cell lines after a 1 h exposure to 1Lgm1-1 ADRt
ADR concentration ADR concentration
at Oh at 2h
Cell line (x 19molj M-3) (x 10- 9molPm-3)
ATW 3.6+1.0 0.21+0.04
PEA 3.4+1.4 0.18+0.03
SAU 4.2+2.0 0.14+0.09
GRA 3.4+1.1 0.17+0.07
OW-1 2.7+ 1.6 0.16+0.02
SKA 2.5+0.7 0.12+0.04
MLS 3.8+1.9 0.18+0.08
Cells were immediately washed after the 1 h exposure and ADR
concentration determined (Oh) or resuspended in ADR-free medium
and ADR determined 2h later. Vales were means +s.d. ofn =6 from
two independent experiments.
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GSH/GSSG ratio. Regarding the first mechanism, the pro-
tective function of GSH has long been suspected and it is
generally accepted that a major mode of action of GSH is
the scavenging, both enzymatically and non-enzymatically, of
toxic free radicals in the environment of critical target sites
such as DNA (Arrick & Nathan, 1984). There is evidence
that free radicals can lead to cell injury and death, and may
also be the underlying mechanism for radiation-induced
cytotoxicity (Adams, 1972) and pulmonary oxygen toxicity
(Nustafa & Tierney, 1978). For ADR, it has been established
that highly reactive, oxygen-centred free radicals such as
superoxide anion (02) and hydroxyl radical ('OH) could be
generated through its reductive metabolism in a cell-free
system (Goodman & Hockstein, 1977; Bachur et al., 1978) as
well as in intact cells in vitro (Sinha et al., 1987; Doroshow,
1986). If such reactive radicals were formed in the present set
of cell lines in vitro it is likely that those cell lines capable of
maintaining a high concentration of GSH probably have
differential advantages over cell lines that fail to maintain
their GSH contents. The importance of GSH has also been
supported by recent studies using buthionine sulphoximine
(BSO), a specific inhibitor of GSH synthesis, which can
greatly increase the sensitivity of tumour cells to a variety of
anti-cancer drugs. For example, when this agent was used to
deplete GSH before ADR exposure, dose-modification
factors between 1.5 and 8 have been observed (Hamilton et
al., 1985; Suzukake et al., 1982; Green et al., 1984; Crook et
al., 1986; Lee et al., 1988; Kramer et al., 1988). Importantly,
the degree of potentiation was shown to be directly related
to the extent of GSH depletion (Lee et al., 1988). Further
evidence for the importance of GSH comes from the data of
Rice and co-workers (1986), who showed that all 19 ADR
resistant clones of the CHO cells isolated by the cloning
rings technique had elevated GSH values. GSH has also
been shown to play a role in determining tumour response to
a variety of chemotherapeutic agents in vivo (Ono & Shrieve,
1986; Tsutsui et al., 1986; Kramer et al., 1987). Of particular
interest is the recent observation that human ovarian tumour
xenografts resistant to melphalan could be made sensitive by
depletion of GSH with BSO (Ozols et al., 1987). Thus, the
involvement of GSH in the protection of tumour cells
against cytotoxic treatment appears to have been convinc-
ingly demonstrated.
The maintenance of a high GSH/GSSG ratio has been
shown to be vital for the functional integrity of cell mem-
branes (Lotscher et al., 1979; Harris & Baum, 1980). It was
shown that unless membrane sulphydryls were kept in a
highly reduced state, the membranes could become leaky,
resulting in the uncontrolled release of Ca2+ into the
cytoplasm from the mitochondria as well as influx from the
extracellular spaces (Lotscher et al., 1979) and this had been
postulated as a 'common pathway' of cytotoxicity for chemi-
cals that induce oxidative stress (Schanne et al., 1979). ADR
was shown not only to form H202 and other oxygen-centred
free radicals during its metabolism (Goodman & Hockstein,
1977; Bachur et al., 1978; Doroshow, 1986; Sinha et al.,
1987), but also to have the ability to kill cells without
entering them, presumably through damage to plasma mem-
branes (Tritton & Yee, 1982; Tokes et al., 1982). Thus it is
entirely possible that cell lines that can maintain a high
GSH/GSSG ratio, because of their greater ability to regener-
ate GSH, may have differential advantage over cell lines that
cannot do so.
The present study showed that the ability of the resistant
cell lines to maintain their GSH contents may be due to their
higher basal rates of GSH synthesis visa vis the 'sensitive'
cell lines. Under normal conditions, GSH synthesis is sub-
jected to feedback inhibition, by GSH itself, of the rate-
limiting enzyme y-glutamyl-cysteine synthetase (Meister &
Anderson, 1983). Upon treatment with ADR, GSH may be
removed spontaneously through reaction with free radicals
or enzymatically through the action of GSH peroxidase and
S-transferase. This removal of GSH would be expected to
alleviate somewhat the feedback inhibitory effect of GSH.
Consequently, the rates of GSH synthesis increased on
average by 4-6% above control value in all cell lines (Figure
4). The difference between 'sensitive' and 'resistant' cell lines
appeared to be that the latter have higher basal rates of
GSH synthesis than the former, and therefore a 4-6%
increase in synthesis rate for the 'resistant' cell lines repre-
sents substantially more GSH in real terms than in the
'sensitive' cell lines. While it is not clear whether the increase
in GSH content in the 'resistant' cell lines was the direct
cause of their intrinsic resistance, or simply a consequence of
their non-susceptibility to the toxic effects of ADR, the well
demonstrated protective effects of GSH against ADR cyto-
toxicity (Hamilton et al., 1985; Ozols, 1985; Yoda et al.,
1986; Lee et al., 1988) would suggest the increase in GSH
content as being a contributing factor.
The development of drug resistance to ADR has been the
subject of intense investigation. Besides the mechanisms
relating to the GSH redox cycle, other possible modes of
resistance included those involving changes in drug transport
and topoisomerase II activity (Glisson et al., 1987). A
number of reports have shown that ADR resistance can be
associated with decreased cellular ADR concentration due to
increased rates of ADR efflux (Harker & Sikic, 1985; Inaba
& Johnson, 1978). More recent studies have linked ADR
efflux with a 170kDa P-glycoprotein located on the plasma
membrane which was 'over-produced' in resistant cells
(Kartner et al., 1983). However, there is a large body of
evidence suggesting that transport changes may not be the
only mechanism responsible for ADR resistance. Thus,
recent reports have shown that a panel of human sarcoma
(Harker et al., 1986) and ovarian tumour (Louie et al., 1986)
cell lines exhibit differential sensitivities to ADR but no
detectable differences in ADR transport. Furthermore, a
significant number of resistant human tumour cell lines have
failed to demonstrate the 170kDa P-glycoprotein presumed
to be responsible for affecting ADR transport (Richert et al.,
1985; Mirski et al., 1987; Fuqua et al., 1987). In other
studies the 170kDa P-glycoprotein was determined to be
important, but not the only mechanism of acquired and de
novo resistance to ADR in human tumour cell lines (Kramer
et al., 1988). Consequently, the identity of the dominant
mechanism(s) of ADR resistance in patients appears to
remain unresolved. The present study also failed to find a
consistent correlation between ADR accumulation and ADR
sensitivity, confirming the idea that at least in some instances
changes in drug transport may not be the predominant
mechanism of resistance. Furthermore, the failure to detect
ADR metabolites in all of the ovarian tumour cell lines
studied (Figure 3 and Louie et al., 1986) strongly implies
that alterations in the metabolic detoxification process were
probably not involved in determining cellular sensitivity to
ADR in the present studies.
In the search for clinical drug resistance, it is important to
use model systems that most closely resemble human
tumours in situ. For this reason the present study used a
panel of human ovarian tumour cell lines established directly
from patients whose treatment histories were known (Table
I). In all cases no further selection had been made in vitro
for drug resistance. It is of note that the difference in
sensitivity to ADR between the most sensitive and the most
resistant lines was only approximately 3-fold, in good
accordance with previous findings using cell lines established
from patients' biopsies with no subsequent selection in vitro
(Louie et al., 1986; Ganapathi et al., 1986; Aida & Bodell,
1987). Significantly, cell lines obtained from previously
untreated patients (SAU and GRA) were among the more
sensitive cell types, whereas cell lines established from
heavily treated, relapsed patients (MLS and SKA) were
among the more resistant cell types (see Tables I and II).
In summary, the present study identified a difference
between ADR 'sensitive' and 'resistant' human ovarian cell
lines in their response to ADR treatment: resistant cell linesCELLULAR GSH CONTENT DURING TREATMENT 297
maintained a high GSH level during drug exposure whereas
sensitive cell lines did not. Consequently, resistant cell lines
had higher GSH AUCs for the duration of ADR exposure
than did sensitive cell lines. Currently, many investigators
believe that resistance to a drug such as ADR, and potential
treatment failure or relapse, may be due to a number of
independent mechanisms. A number of these have been
identified (Lee et al., 1988; Harker et al., 1986; Harker &
Sikic, 1985, 1986; Louie et al., 1986; Ganapathi et al., 1986;
Aida & Bodell, 1987; Inaba & Johnson, 1978; Harris et al.,
1979; Siegfried et al., 1983; Kartner et al., 1983; Richert et
al., 1985; Rice et al., 1986). The present study suggests that
alterations in GSH level during ADR exposure may be an
important factor in drug resistance and should merit further
investigation.
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